Advertisement

Topics

NightstaRx Raises $45M to Fund Phase III Study with Retinal Disease Gene Therapy

05:12 EDT 30 Jun 2017 | Genetic Engineering News

U.K. firm NightstaRx raised $45 million in a Series C financing round to support continued clinical development of its pipeline of retinal gene therapies, including a pending Phase III study with lead candidate NSR-REP1 for treating choroideremia. The new funds will also be used to support an ongoing Phase I/II study with NSR-RPGR in patients with X-linked retinitis pigmentosa (RP), and a proposed Phase I/II trial with a gene therapy product targeting an inherited form of macular dystrophy. Nightstar projects starting the macular dystrophy clinical trial during late 2018. Investors in the Series C round included Nightstar’s existing investors Syncona and New Enterprise Associates (NEA), and new investors Wellington Management Company and Redmile Group. “As an original investor in Nightstar, our goal from day one was to build a global gene therapy leader with the capability of developing multiple programs for inherited retinal diseases,” commented Chris Hollowood, chairman ...

Original Article: NightstaRx Raises $45M to Fund Phase III Study with Retinal Disease Gene Therapy

NEXT ARTICLE

More From BioPortfolio on "NightstaRx Raises $45M to Fund Phase III Study with Retinal Disease Gene Therapy"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...